RECEIVED

AUG 2 1 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231, ON 14 August 2002

_____
AGENT/ATTORNEY FOR APPLICANTS

14 AUGUST 2002
_____
DATE

Attorney Docket No. GM50057

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Ferguson, *et al.*	14 August 2002
Serial No.:	10/019,369	Group Art Unit No.: Unknown
Filed:	13 November 2001	Examiner: Unknown
For:	Methods of Modulating Activity of Prokaryotic Ribosomes	

Assistant Commissioner for Patents
Washington, D.C. 20231

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and Certification under 37 C.F.R. §1.97(e)(1) or (e)(2)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except for those references already part of the filewrapper. This statement is being filed with the required Certification and without any fee, in accordance with the provisions of 37 C.F.R. §1.97(c)(1) and (2), i.e., before a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311.

Serial No.: 10/019,369
Group Art Unit No.: Unknown

Statement of Certification. The undersigned hereby certifies either:

(a)   that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, or

Respectfully submitted,

Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\ERG\APPS\micro\50057\US National\IDSsearchreport.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO.	APPLICATION NO.
		GM50057	10/019,369
INFORMATION DISCLOSURE STATEMENT **BY APPLICANT** *(Use several sheets if necessary)*		APPLICANT Ferguson, *et al.*	
		FILING DATE	GROUP
		13 November 2001	Unknown

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes	No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AA	"E. coli ribosomal operon rrnB encoding the 16S ribosomal RNA", GenBank Accession Number V00348, 07/13/1983.
	AB	Porse, *et al.*, "Sites of Interaction of Streptogramin A and B antibiotics in the Peptidyl Transferase Loop of 23 S rRNA and the Synergism of their Inhibitory Mechanisms", *Journal of Molecular Biology*, 286: 375-387 (1999).
	AC	Macbeth, *et al.*, "The Phonotype of Mutations of G2655 in the Sarcin/Ricin Domain of 23 S Ribosomal RNA", *Journal of Molecular Biology*, 285: 965-975 (1999).
	AD	Poulson, *et al.*, "The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome", *Molecular Microbiology*, 41: 1091-1099 (2001).
	AE	Copy of Partial European Search Report.

EXAMINER	DATE CONSIDERED

·EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

N:\ERG\APPS\micro\50057\US National\1449-1.doc